← Back to patent-cliff list
Nuzefatide pevedotin
Tier C — Watch / tradeNuzefatide pevedotin
Bicycle Tx Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：EphA2
Indications (approved)：Solid tumour, 胰腺导管癌, Non-small cell lung cancer, Ovarian cancer, 三阴性乳腺癌, Head and neck cancer, 转移性上皮癌
Regional status
US
Phase II
2019-11-07
EU
Phase II
2019-11-07
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Nuzefatide pevedotin?
Approved indications include: Solid tumour, 胰腺导管癌, Non-small cell lung cancer, Ovarian cancer, 三阴性乳腺癌, Head and neck cancer, 转移性上皮癌.
When does the Nuzefatide pevedotin patent expire?
No public expiry year is available for Nuzefatide pevedotin yet; this page updates once verified.
How do I get a quote for Nuzefatide pevedotin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07